Therefore, the possibility to target tumor cells through epigenetic approaches, in particular by modulating HDAC activity, has emerged as a promising pharmacological tool for cancer therapy and several HDAC inhibitors have entered clinical trials in the last few years [43]. Here, HDAC9 is linked to neoplasm.